AKT1 and hepatocellular carcinoma: In combination with our findings that FOXM1-UBE2S enhances cell chemoresistance through AKT signaling in HCC, these results demonstrate that the influence of UBE2S on the prognosis of patients with HCC is AKT-dependent.